Vesto Therapeutics, Inc.

According to its NIH grant abstract, Vesto Therapeutics has developed de novo designed minibinder proteins that can be radiolabeled, and plans to apply this minibinder radioconjugate platform to the prostate cancer targets B7-H3 and STEAP1. Source

Keywords: minibinder radioconjugate radiotheranostics B7-H3 STEAP1 prostate cancer Show all 6 keywords